Clinical trials: Influenza H1N1
Bacterial Growth, Novel Influenza A (H1N1)
The Research of Novel Electrolyzed Water Spray to Eradicate Bacteria E-coli and an Attenuated Human Flu Virus
The purpose of this study is to test whether spraying the hand of patients by use of the novel electrolyzed water spray will decrease the number of bacteria E-coli and the virus titer of an attenuated human flu virus.
- Trial name
- NCT05797103
- Testing
- A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Dove Medical Press Ltd
Influenza, Human
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection.
- Trial name
- NCT01014988
- Testing
- zanamivir aqueous solution
- Where
- 110 sites in United States, Australia and 11 more
- Volunteers
- 202 people
- Sponsor
- GlaxoSmithKline
Influenza Infection
Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device
Primary objective: To evaluate the safety and immunogenicity of low-dose ID S-OIV H1N1 vaccines delivered via a novel microneedle device (MicronJet600) and compare this to the full-dose standard IM injection.
- Trial name
- NCT01049490
- Testing
- S-OIV H1N1 vaccine
- Where
- China
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza A
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
The primary objective is to determine the dose level of live, wild-type A/California/ H1N1 2009 virus that has an appropriate safety and illness/infectivity profile to be used as an influenza virus, challenge strain in future…
- Trial name
- NCT02014870
- Testing
- 1:1000 Live wild-type A/California/H1N1 2009, 1:100 Live wild-type A/California/H1N1 2009, 1:10 Live wild-type A/California/H1N1 2009
- Where
- Belgium
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
HIV Infection
Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults
This is a randomized, open label, phase II trial to evaluate the safety and immunogenicity of two different schedules of vaccination against influenza A H1N1 in HIV-infected individuals, in which each of the randomized groups…
- Trial name
- VIP-H1N1 (NCT01155037)
- Testing
- Adjuvanted vaccine against H1N1 influenza virus (GSK)
- Where
- Brazil
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
The purpose of this study is to determine the preferred dose of H1N1 pandemic influenza vaccine in a pediatric population, aged 6 months to 17 years, based upon assessments of immunogenicity and safety.
- Trial name
- NCT00976469
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated), Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011
- Where
- 6 sites in Austria, Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
H1N1 Vaccine in Pregnant Women
The purpose of this study is to evaluate an investigational 2009 H1N1 influenza vaccine to determine vaccine safety in pregnant women and the body's immune response (body's defense against disease) to different strengths of the…
- Trial name
- NCT00963430
- Testing
- Inactivated H1N1 Vaccine
- Where
- 5 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy, Immunosuppressed
Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva
This study aims to identify clinical symptoms and outcomes, as well as response to anti-viral treatment in children living in Geneva, with influenza A/ H1N1 infection during the current pandemic.
- Conditions
- Healthy, Immunosuppressed, Asthmatic, Neuromuscular Diseases
- Trial name
- NCT01022931
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University Hospital, Geneva
Influenza H1N1
Non-specific Response to H1N1 Vaccine
This is a prospective observational study with recruitment of healthy volunteers from consecutive recipients of H1N1 influenza vaccine at the University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
- Trial name
- NCT01178918
- Where
- Slovenia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
- Trial name
- NCT00938639
- Testing
- CSL425
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT00943488
- Testing
- Inactivated H1N1 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
The purpose of this study was to demonstrate the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza. The study was a placebo controlled, double blinded trial at a single site.
- Trial name
- NCT01688297
- Testing
- VXA-A1.1 Oral Vaccine
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine
The study hypothesis is that two 0.5 ml doses of non-adjuvanted whole virion monovalent A/H1N1 influenza vaccine (IVACFLU)--each dose with an HA content of 15 mcg from A/California/07/2009 (H1N1)-like virus--will be safe and…
- Trial name
- NCT01507779
- Testing
- IVACFLU
- Where
- Vietnam
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children.
- Trial name
- NCT00972816
- Testing
- MF59-eH1N1
- Where
- 35 sites in United States, Mexico
- Volunteers
- 1,357 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00953524
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)
- Where
- 15 sites in United States
- Volunteers
- 849 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age.
- Trial name
- NCT00976820
- Testing
- GSK2340274A, GSK2340273A
- Where
- 30 sites in United States, Canada
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Narcolepsy
Risk of Narcolepsy Associated With Administration of H1N1 Vaccine
The goal of the study is to assess the risk of occurrence of narcolepsy following the administration of inactivated (AS03) adjuvanted A/H1N1 pandemic influenza vaccine in the province of Quebec, Canada, using different case…
- Trial name
- NCT01394614
- Testing
- A/H1N1 vaccine
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Acute Respiratory Distress Syndrome, Influenza
STIP: Statin Trial for Influenza Patients
To assess the efficacy and safety of oral rosuvastatin in patients with suspected or confirmed influenza who require intensive care unit (ICU) admission due to respiratory distress.
- Conditions
- Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
- Trial name
- STIP (NCT00970606)
- Testing
- Rosuvastatin (crestor)
- Where
- 21 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gordon Bernard
Novel (H1N1) Influenza
Virus Shedding and Environmental Deposition of a Novel Influenza Virus
An influenza pandemic has recently been declared, involving the novel A(H1N1) 'swine flu' virus. This has spread to almost 100 countries worldwide in less than two months, causing widespread disease so far in Mexico, USA and…
- Trial name
- NCT01046734
- Where
- 3 sites in United Kingdom
- Volunteers
- 105 people
- Sponsor
- University of Nottingham
Influenza
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk…
- Trial name
- IRC003 (NCT01227967)
- Testing
- Amantadine, Ribavirin, Oseltamivir, Oseltamivir
- Where
- 91 sites in United States, Argentina and 3 more
- Volunteers
- 881 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)